Mary S. Campbell

发表

Results of a phase 2 study of pacritinib ( SB 1518 ) , a JAK 2 / JAK 2 ( V 617 F ) inhibitor , in patients with myelo fi brosis

L. To, A. Roberts, M. Wadleigh, 2015 .

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

L. To, A. Roberts, M. Wadleigh, 2015, Blood.

Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.

M. Galsky, E. Heath, A. Balar, 2022, European urology.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

R. Advani, J. Vose, A. LaCasce, 2018, Blood.

SGNBCMA-001: A phase 1 study of SEA-BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma.

C. Jacquemont, J. Hoffman, M. Schroeder, 2019, Journal of Clinical Oncology.

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

M. Harrison, S. Park, E. Heath, 2021 .

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

T. Powles, J. Rosenberg, T. Kojima, 2022, Cancer medicine.

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

S. Verstovsek, R. Mesa, J. Dean, 2013 .